Photo courtesy of Merck.
Merck will tap Janux’s Tumor Activated T Cell Engager (TRACTr) tech to engineer new drug candidates against two cancer targets selected by Merck.

Photo courtesy of Merck. Merck will tap Janux’s Tumor Activated T Cell Engager (TRACTr) tech to engineer new drug candidates against two cancer targets selected by Merck.

Merck has entered an agreement with San Diego-based biotech Janux Therapeutics in a deal valued at more than $1 billion...